Pulmonary systemic sclerosis

This study tests whether the drug nerandomilast can slow lung scarring in people with autoimmune diseases like rheumatoid arthritis or scleroderma. About 400 adults whose lung function hasn't improved with standard treatment will take either nerandomilast or a placebo twice daily…

This study looks at the long-term safety and effectiveness of belimumab in adults with lung scarring (interstitial lung disease) caused by systemic sclerosis or other connective tissue diseases. About 514 people who completed earlier trials will receive belimumab for up to severa…

This study tests whether belimumab (Benlysta), a drug already used for lupus, can improve lung function and skin thickening in adults with scleroderma-related interstitial lung disease. About 300 participants will receive either belimumab or a placebo added to their standard care…

This study tests whether new investigational drugs can improve lung function in people with scleroderma-related lung scarring. About 400 adults with this condition will receive either the study drug or a placebo for 52 weeks. The main goal is to see if the drug helps preserve or …

This trial tests whether adding rituximab to standard mycophenolate mofetil (MMF) therapy can improve lung function in people with severe lung scarring caused by systemic sclerosis. About 102 adults with this condition will receive either rituximab infusions plus MMF or placebo i…

This study is for people with scleroderma who also have lung scarring (interstitial lung disease). It compares two treatments: a double immunosuppression regimen (rituximab plus mycophenolate mofetil) versus the same double therapy plus an anti-fibrotic drug (nintedanib or pirfen…

This early-phase study tests whether a special PET scan tracer, 18F-fluoroglutamine, can detect pulmonary arterial hypertension (PAH) earlier and more accurately. PAH is a serious disease of the lung's blood vessels that often goes undiagnosed for years. The study will scan 71 ad…

Scleroderma often scars the lungs, which can weaken breathing muscles and make exercise harder. Researchers want to know whether pelvic floor problems, such as incontinence or pelvic pain, go hand in hand with these lung and breathing changes. The study enrolls 67 women with scle…

This registry is following 3,000 adults with idiopathic pulmonary fibrosis (IPF) or other chronic fibrosing interstitial lung diseases (ILDs) to understand how these conditions progress over time. Researchers collect information on symptoms, treatments, quality of life, and store…

This study is for children and adults with interstitial lung disease, a group of conditions that scar the lungs and make breathing hard. Researchers will follow 3000 patients and their relatives for up to 10 years, collecting medical data and genetic information. The goal is to l…

This study is testing whether artificial intelligence (AI) can better detect a serious lung condition called pulmonary arterial hypertension (PAH) in people with scleroderma. Researchers will compare AI algorithms to traditional screening methods in 350 patients across multiple h…

This study collects blood, airway, and urine samples from 2,000 healthy volunteers and people with lung diseases like COPD and pulmonary fibrosis. Researchers will compare samples to establish normal ranges and learn how genes change in lung disease. The goal is to better underst…

This study looks at how hormones and metabolism are involved in pulmonary arterial hypertension (PAH), a serious lung condition. Researchers will measure sex hormone levels, insulin resistance, and test two potential treatments—metformin and ACE-2—in small groups. The goal is to …